[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

December 2022 | 83 pages | ID: IF147D0652EAEN
Global Markets Direct

US$ 3,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Interleukin-1 receptor-associated kinase 4 (IRAK-4) is a protein kinase involved in signaling innate immune responses from Toll-like receptors. Mutations in IRAK-4 result in IRAK4 deficiency and recurrent invasive pneumococcal disease. It phosphorylates E3 ubiquitin ligases Pellino proteins to promote pellino-mediated polyubiquitination of IRAK1. Ubiquitin-binding domain of IKBKG/NEMO binds to polyubiquitinated IRAK1 bringing together the IRAK1-MAP3K7/TAK1-TRAF6 complex and the NEMO-IKKA-IKKB complex. MAP3K7/TAK1 activates IKKs leading to NF-kappa-B nuclear translocation and activation.

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) pipeline Target constitutes close to 24 molecules. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 8, 10 and 2 respectively. Report covers products from therapy areas Immunology, Oncology, Dermatology, Gastrointestinal, Metabolic Disorders, Cardiovascular, Central Nervous System, Infectious Disease, Musculoskeletal Disorders and Undisclosed which include indications Rheumatoid Arthritis, Inflammation, Atopic Dermatitis (Atopic Eczema), Myelodysplastic Syndrome, Autoimmune Disorders, Diffuse Large B-Cell Lymphoma, Psoriasis, Chronic Myelomonocytic Leukemia (CMML), Follicular Lymphoma, Hidradenitis Suppurativa, Inflammatory Bowel Disease, Lymphoma, Unspecified Cancer, Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Coronavirus Disease 2019 (COVID-19) Pneumonia, Cutaneous Lupus Erythematosus, Diabetic Nephropathy, Esophageal Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Gouty Arthritis (Gout), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Leukemia, Lupus Erythematosus, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Melanoma, Multiple Sclerosis, Pancreatic Ductal Adenocarcinoma, Primary CNS Lymphoma, Rosacea, Solid Tumor, Systemic Lupus Erythematosus, Type 1 Diabetes (Juvenile Diabetes) and Unspecified.

The latest report Interleukin 1 Receptor Associated Kinase 4 - Drugs In Development, 2022, outlays comprehensive information on the Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape for Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1)
  • The report reviews Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Overview
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
Asahi Kasei Pharma Corp
Astellas Pharma Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
Bayer AG
Beijing Hanmi Pharmaceutical Co Ltd
Bristol-Myers Squibb Co
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Emmaus Life Sciences Inc
Evommune Inc
Fresh Tracks Therapeutics Inc
Gilead Sciences Inc
Kurome Therapeutics Inc
Kymera Therapeutics Inc
Nyrada Inc
Pfizer Inc
Rigel Pharmaceuticals Inc
TG Therapeutics Inc
Xi'An Yufan Biotechnology Co Ltd
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Drug Profiles
AK-179 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AS-2444697 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AZD-6793 - Drug Profile
Product Description
Mechanism Of Action
BAY-1830839 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BMS-986126 - Drug Profile
Product Description
Mechanism Of Action
History of Events
emavusertib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
EVO-101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
FRTX-02 - Drug Profile
Product Description
Mechanism Of Action
History of Events
GS-5718 - Drug Profile
Product Description
Mechanism Of Action
History of Events
IRAK4 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KM-10544 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KT-413 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KT-474 - Drug Profile
Product Description
Mechanism Of Action
History of Events
R-289 - Drug Profile
Product Description
Mechanism Of Action
History of Events
R-835 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit IRAK4 for Rheumatoid Arthritis and Unspecified Cancer - Drug Profile
Product Description
Mechanism Of Action
Small Molecules 1 to Inhibit IRAK4 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit IRAK1 and IRAK4 for Acute Myelocytic Leukemia and Myelodysplastic Syndrome - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit IRAK4 for Autoimmune Disorders, Cardiovascular Disease, Inflammation and Oncology - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit IRAK4 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
History of Events
TQH-3821 - Drug Profile
Product Description
Mechanism Of Action
zabedosertib - Drug Profile
Product Description
Mechanism Of Action
History of Events
zimlovisertib - Drug Profile
Product Description
Mechanism Of Action
History of Events
ZYF-0116 - Drug Profile
Product Description
Mechanism Of Action
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Dormant Products
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Discontinued Products
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Stage and Molecule Type, 2022


More Publications